DDG 2025 Research: Presentation by Michael Roden, MD

Target RWE is proud to feature a significant new study presented at DDG 2025 by our esteemed MASH Steering Committee member, Dr. Michael Roden. Titled "Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH in a real-world setting," this research delves into the critical impact of liver biopsy fibrosis stage and its dynamic changes over time on severe clinical outcomes in MASLD/MASH patients.

Utilizing robust real-world data, this study offers invaluable insights into how disease progresses outside of controlled clinical trial environments, providing a deeper understanding of patient journeys and the long-term implications of fibrosis. View Dr. Roden's compelling video presentation to explore these findings further.